SCHEMBL1014494

SCHEMBL1014494

CCOc1ccc(OCC2CCC(CC=O)CC2)c(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
HTR2B P41595 2/20 0.36
RIPK1 Q13546 1/20 0.36
PDE4B Q07343 5/20 0.36
PDE4A P27815 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
VEGFA P15692 1/20 0.35
KDM1A O60341 2/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
BRD4 O60885 1/20 0.34
SLC6A9 P48067 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014683 0.87 HTR2A (0.37) HTR2AHTR2CHTR2BRIPK1PDE4B
SCHEMBL4320971 0.85 HPGD (0.33) HTR2CHTR2BKDM1AALDH1A1LMNA
SCHEMBL15445798 0.83 RIPK1 (0.41) HTR2AHTR2CHTR2BRIPK1PDE4B
SCHEMBL13929892 0.81 HPGD (0.40) HTR2AHTR2CHTR2BRIPK1PDE4B
SCHEMBL28549719 0.81 HPGD (0.40) HTR2AHTR2CHTR2BRIPK1PDE4B
SCHEMBL2261945 0.81 CTSL (0.40) HTR2AHTR2CHTR2BRIPK1
SCHEMBL2261954 0.81 CTSL (0.40) HTR2AHTR2CHTR2BRIPK1
SCHEMBL26770363 0.80 HTR2C (0.47) HTR2AHTR2CHTR2BRIPK1PDE4B
SCHEMBL19445468 0.80 HTR2A (0.39) HTR2AHTR2CHTR2BRIPK1PDE4B
SCHEMBL15445797 0.80 RIPK1 (0.42) HTR2AHTR2CHTR2BRIPK1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2272837-B1 LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORP (JP) 2014-12-17 EP disclosed
US-7914862-B2 Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION (JP) 2011-03-29 US disclosed
EP-2272837-A1 LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE Chisso Corporation (JP) 2011-01-12 EP disclosed
US-20090278088-A1 LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090278088-A1 LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD2, OCIAD1, CCDC22 HTR2A 1041/4885HTR2C 657/4885HTR2B 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.